Epstein Secrets

w. One is a high-level concept piece on the global healthcare venture fund idea that we prepared to help David introduce the concept to folks around Carlyle. It provides an overview of the market opportunity as we see it, though of course with much less detail around investment strategy and emphases tha

n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C

FW: Materials at request of David Rubenstein Date: Tue, 04 Feb 2014 07:51:42 +0000 Attachments: NaviMed_Global_PPM_Draft_4-18-11_pdf PPM from the Carlyle Check out 10 years plus 31 Board of Advisors structure etc very similar. 2.5% fee. Co-investments, parallel funds etc. B From: Ryan Schwarz [ma

n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C

w. One is a high-level concept piece on the global healthcare venture fund idea that we prepared to help David introduce the concept to folks around Carlyle. It provides an overview of the market opportunity as we see it, though of course with much less detail around investment strategy and emphases tha

n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C